Navigation Links
UCI non-small cell lung cancer study highlights advances in targeted drug therapy
Date:11/1/2010

Orange, Calif., Nov 1, 2010 A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

The multicenter study is testing whether the drug crizotinib effectively slows, stops or reverses growth in advanced non-small cell lung cancer tumors by targeting a genetic mutation that causes uncontrolled tumor growth. Study participants all tested positive for a mutation in the anaplastic lymphoma kinase gene.

According to the findings, tumors disappeared or shrank in 57 percent of patients. Tumors ceased growing in another 33 percent. The response rate to the current standard of care for advanced non-small cell lung cancer is about 15 percent.

"For the majority of patients, the treatment right now is chemotherapy plus targeted therapy in those eligible," said Dr. Ignatius Ou. "In the future, with the advance of personalized medicine, we hope to be able to identify specific genetic change in the lung cancer and treat patients with specific inhibitors that can improve survival rates and quality of life."

The New England Journal of Medicine article includes data from 82 patients treated in Phase 1 of this study, sponsored by the pharmaceutical company Pfizer. The targeted genetic mutation is particularly prevalent among those who have never smoked. Study participants ranged in age from 25 to 78, with 76 percent of them nonsmokers.

Ou treated 15 patients in UCI's Phase 1 trial, most from Los Angeles, Orange and San Diego counties. One person came from Arizona each month for treatment and assessment. Ou is currently enrolling patients in Phase 2 and 3 trials for crizotinib. Interested candidates should contact the UCI clinical trials office at 714-456-6241.

Each year, about 1.5 million new cases of lung cancer are diagnosed globally. Nearly 75 percent of people with non-small cell lung cancer are diagnosed at an advanced stage, for which the five-year survival rate is only 6 percent.

Recent cancer research emphasizes targeting, or personalizing, treatment through molecular analysis of a tumor and the use of a specific drug to inhibit genetic expression. Conventional chemotherapy bombards a tumor with multiple drugs.

According to the National Cancer Institute, because targeted cancer therapies are more selective for cancer cells, they may harm fewer normal cells, reduce side effects and improve quality of life.


'/>"/>

Contact: John Murray
jdmurray@uci.edu
714-456-7759
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
2. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
3. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
4. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
5. Comparision of overall survival for non-small cell lung cancer patients
6. Enhancing arrest of cell growth to treat cancer in mice
7. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
8. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
9. Low forms of cyclin E reduce breast cancer drugs effectiveness
10. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
11. Soft drinks may increase risk of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... ... , ... At its annual meeting held last week, the American Parkinson Disease ... of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are pleased ... APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he was ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
(Date:2/5/2016)... ... 05, 2016 , ... On June 9-10, Las Vegas will ... education (CME) event presented by the Association for Comprehensive Care in Rare Diseases ... whose mission is to provide education, tools, and resources to primary care clinicians ...
(Date:2/5/2016)... Luis Obispo, CA (PRWEB) , ... February 05, 2016 , ... ... new changes that Medicare San Luis Obispo users can expect to see in 2016. ... , The two most significant changes will directly impact many San Luis Obispo seniors ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
Breaking Medicine Technology: